Hépatite C chronique: épidémiologie, diagnostic et traitement au CHU Yalgado-Ouédraogo de Ouagadougou

Sombié, Roger; Bougouma, A.; Somda, Sosthène; Sangaré, Lassana; Lompo, Olga Mélanie; Kabore, Z.; Tiéno, H.; Drabo, Joseph; Ilboudo, D.

doi:10.1007/s12157-010-0213-7

Cited by 7 publications

(5 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They were 42.3 years old for VHB which is consistent with other studies carried out in Côte d'Ivoire that found an average age of 42 years for chronic carriers of HBs Ag [9] and 40 [10], in France HBV patients had a median age of 44 years [11]. Our HCV patients were on average 51.9 years old, in line with SOMBIE et al who found an average age of 51 ± 6.9 years in HCV patients put on treatment [6] and a study in Morocco where HCV patients were on average 52 years old [12], in Tunisia the average age of HCV patients was 50 years [13] and 53.1 ± 8.1 years in Cameroon [7]. HCV Japanese patients had an average age of 55 years [14].…”

Section: Discussionsupporting

confidence: 92%

“…Our sex ratio was 1.56. Which is higher than HCV patients in Burkina Faso 1.25 [6] and in Tunisia whose patients had a sex ratio of 1.04 [13] but is consistent with Japanese patients who had a sex ratio of 1.57 [14].…”

Section: Discussionsupporting

confidence: 62%

“…In our study, out of 1860 patients seen in hepatogastroenterology consultation, 422 that is 24.7% had chronic hepatitis B or C. Only 44 patients that is 10.4% had had access to treatment with PEG-IFN free. In Gabon 4.5% of HBV and 9.8% of HCV were put on treatment [5], while in Burkina Faso [6] 39% of HCV patients were treated in a public hospital. A study in Cameroon in a private medical center treated 73.17% of HCV patients [7].…”

Section: Discussionmentioning

confidence: 99%

“…A dosage reduction in treatment was reported in 23 patients (16.3%), in all cases due to adverse hematological effects [13]. Sombié et al noted 1 anemia in 2/18, leukopenia in 6/18 and thrombocytopenia in 2/18 [6]. In Cameroon out of 90 patients who were treated for at least 12 weeks, 6 (6.7%) discontinued treatment because of adverse events (neutropenia, encephalitis, pancytopenia and thrombocytopenia) [7].…”

Section: Hematological Side Effectsmentioning

confidence: 99%

See 3 more Smart Citations

Treatment of Chronic Viral Hepatitis with Pegylated Interferon in Ivory Coast

Anzouan-Kacou

Bangoura

Djenabou

et al. 2016

OJGas

View full text Add to dashboard Cite

Background: In the Ivory Coast, chronic infection by hepatitis B and C virus is the leading cause of cirrhosis and hepatocellular carcinoma. The absence of universal health coverage makes the treatment inaccessible to all. Objectives: To assess the efficacy of Pegylated Interferon in clinical practice in patients with chronic viral hepatitis B and C and determine the hematologic side effects. Patients and Methods: A descriptive retrospective study from January 2012 to November 2013 on a cohort of patients chronic carriers of hepatitis B virus (n = 11) treated with Pegylated Interferon to 180 mcg per week and hepatitis C virus (n = 30) treated with a combination therapy associating pegylated Interferon to 180 mcg per week and Ribavirin assayed according to the genotype. Results: Out of 1860 patients seen in hepatogastroenterology consultation 422 had viral hepatitis B or C that is a prevalence of 22.7% and 41 patients were treated (9.7%) by Pegylated Interferon. Among these 41 patients mentioned earlier, 30 had HCV (73.17%) with a case of HIV + HVC co-infection, 11 patients had HBV (26.83%) including 3 cases of HBV + HDV co-infection. Patients' age ranged from 24-69 years with an average of 49.2 ± 12.2 years including 46.5 years for HBV and 51.9 years for HCV. The sex ratio was 1.56. The original transaminases were on average 93.37 IU/l for AST and 110.47 for ALT. The average RNA HCV was 1,685,331 IU/ml and the DNA HBV 33,312,767 IU/ml. Patients with HCV were of genotype 1 in 56.66%, genotype 2 in 40% and one case of genotype 4 (3.34%) from Central Africa. Fibrosis score at institution of treatment was significant (≥A2 and/or ≥F2) in 86.9% of cases of Fibrotest®, 100% of cases of Fibrometer®. We observed 48.8% of neutropenia < 750/mm 3 , 33.3% of anemia and 29.3% of thrombocytopenia < 100,000/mm 3. There was no dose reduction of Pegylated Interferon and Ribavirin. For HBV there were 3 partial responses, 3 responders including 1 HBV + HDV co-infected non responder to HDV, 2 non responders including 1 HBV + HDV co-infected to Week 48. For HCV, there was 52.94% of cases of sustained viral response (SVR) including 44.44% of genotype 1, 83.33% of genotype 2 and 100% of genotype 4. Conclusion: The free antiviral treatment program helped treat 10% of chronic viral hepatitis B and C. Our results are not different from those of the literature. Difficulties remain in the performance of non supported diagnostic tests.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 62%

Section: Discussionmentioning

confidence: 99%

Section: Hematological Side Effectsmentioning

confidence: 99%

See 2 more Smart Citations

Treatment of Chronic Viral Hepatitis with Pegylated Interferon in Ivory Coast

Anzouan-Kacou

Bangoura

Djenabou

et al. 2016

OJGas

View full text Add to dashboard Cite

show abstract

“…Kowo et al [8] in 2018 in Cameroon had found a mean age close to ours (44.24±8.22 years). Sombié et al [9] in Burkina Faso in 2011 also found a mean age of 47 years. The young age of patients in these sub-Saharan studies could be explained by risky procedures such as scarification.…”

Section: Discussionmentioning

confidence: 90%

Hepatitis C Virus Infection: Epidemiological, Diagnostic and Therapeutic Aspects at the Departmental and Teaching Hospital of Borgou-Alibori

CA,

et al. 2023

AustinJInfectDis

View full text Add to dashboard Cite

Introduction: Hepatitis C Virus (HCV) infection is a global public health problem. The epidemiology of this condition in Parakou is still poorly understood. The aim of this study was to investigate the epidemiological, diagnostic and therapeutic aspects of hepatitis C virus infection in the internal medicine department of the Departmental and Teaching Hospital of Borgou-Alibori (DTH-B/A), Parakou. Patients and Methods: This was a descriptive cross-sectional study with retrospective data collection. It concerned patients received in hepato-gastroenterology consultation from 1st January, 2017 to 30 June, 2021. Patients who had undergone a minimal pre-therapeutic workup, which included testing for hepatitis C virus antibodies (anti-HCV Ac) and quantification of viral RNA by PCR, were included. The data were collected from each patient’s medical record and transcribed on a pre-established collection form. Analysis was performed using Epi Info software version 7.2. Results: During the study period, 2786 patients were seen in hepato-gastroenterology consultations. Among them, 142 patients (5.1%) were HCV-positive. Of these seropositive patients, 73 (51.4%) met the inclusion criteria and were selected for the present study. The mean age was 45.5±14.7 years. Thirty-nine (53.4%) were male, for a sex ratio of 1.2. Forty-seven (64.4%) had progressive HCV infection with detectable RNA, including 3 (6.4%) at the stage of liver cirrhosis. Treatment was indicated in these 47 patients (64.4%) and was effective in 35 (74.5%). In all these patients, the HCV RNA test at the control PCR at least three months after the end of treatment was negative (undetectable RNA), representing a sustained virological response of 100%. Conclusion: At DTH-B/A, HCV infection most often affects young adult males. Viremic forms are in the majority. Treatment with direct-acting antivirals remains highly effective.

show abstract

Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda: Table 1.

Riedel

Taylor

Simango

et al. 2016

Trans R Soc Trop Med Hyg

View full text Add to dashboard Cite

There were 69 evaluable patients. HCV genotype 4(61%, 42/69) predominated. 24-week SVR was 70%(26/37) by per-protocol and 32%(26/69) by intention-to-treat analysis. HCV treatment in Rwanda is feasible. SVR with interferon/ribavirin was acceptable in the per-protocol analysis. Transition to newer direct acting antivirals is urgently needed in Rwanda and sub-Saharan Africa more generally to improve treatment outcomes.

show abstract

Hépatite C chronique: épidémiologie, diagnostic et traitement au CHU Yalgado-Ouédraogo de Ouagadougou

Cited by 7 publications

References 28 publications

Treatment of Chronic Viral Hepatitis with Pegylated Interferon in Ivory Coast

Treatment of Chronic Viral Hepatitis with Pegylated Interferon in Ivory Coast

Hepatitis C Virus Infection: Epidemiological, Diagnostic and Therapeutic Aspects at the Departmental and Teaching Hospital of Borgou-Alibori

Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda: Table 1.

Contact Info

Product

Resources

About